Form 8-K - Current report:
SEC Accession No. 0001213900-24-096104
Filing Date
2024-11-12
Accepted
2024-11-12 06:05:22
Documents
15
Period of Report
2024-11-11
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0220621-8k_unicycive.htm   iXBRL 8-K 24607
2 PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED NOVEMBER 11, 2024 ea022062101ex99-1_unicycive.htm EX-99.1 17139
3 GRAPHIC ex99-1_001.jpg GRAPHIC 5064
  Complete submission text file 0001213900-24-096104.txt   229684

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE uncy-20241111.xsd EX-101.SCH 3018
5 XBRL LABEL FILE uncy-20241111_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE uncy-20241111_pre.xml EX-101.PRE 22361
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0220621-8k_unicycive_htm.xml XML 3783
Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

EIN.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40582 | Film No.: 241442799
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)